Loxapine low dose inhalation - Alexza Pharmaceuticals

Drug Profile

Loxapine low dose inhalation - Alexza Pharmaceuticals

Alternative Names: AZ-104; Staccato loxapine low dose

Latest Information Update: 30 Jun 2014

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alexza Pharmaceuticals
  • Class Antipsychotics; Dibenzoxazepines; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Suspended Migraine

Most Recent Events

  • 14 Sep 2009 The primary endpoint was not met in efficacy data from a phase IIb trial in Migraine released by Alexza
  • 11 Sep 2009 Suspended - Phase-II for Migraine in USA (Inhalation)
  • 30 Jun 2009 Alexza completes enrolment in its phase IIb trial for Migraine in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top